Generics:Sodium Valproate 133.2mg
Sodium Valproate
Valex is indicated for the treatment of all types of epilepsy, e.g. Partial seizures, Absence seizures (petit mal), Generalized tonic-clonic seizures (grand mal), Myoclonic seizures, Atonic seizures, Mixed seizures that include absence attack, Prophylaxis of febrile convulsion, Prophylaxis of post-traumatic epilepsy. It is also indicated in the treatment of bipolar disorder & prophylaxis of migraine.
The primary component in this formulation, sodium valproate, has anti-epileptic properties and can be used to treat a variety of seizures. The mechanism through which Sodium Valproate works as an anti-epileptic has yet to be discovered. However, it has been proposed that its action is linked to increased gamma-aminobutyric acid levels in the brain (GABA).
Sodium Valproate tablets may be given once or twice daily. Sodium Valproate syrup should be given in divided doses.
Epilepsy-
Febrile convulsion: 20-30 mg/kg/day in 3 divided doses.
Bipolar disorder: Initially 20-30 mg/kg/day in 2-3 divided doses; adjust dosage in 3-5 days. Maintenance dosage is 1000-2000 mg/day.
Prophylaxis of migraine: 300 mg twice daily, although some may require 1000 mg daily.
Sodium vaiproate appears to impede drug metabolism in a non-specific manner. Phenobarbital, Phenytoin, Warfarin, Aspirin, and other drugs with which it interacts the most are Phenobarbital, Phenytoin, Warfarin, and Aspirin.
Patients with documented hypersensitivity to the medication as well as liver disease should avoid sodium valproate. Sodium Valproate is not recommended for use during pregnancy or in women who may become pregnant.
Anorexia, nausea, and vomiting are the most prevalent adverse effects. The usage of enteric coated pills, on the other hand, reduces these adverse effects. Sedation, ataxia, and tremor are all CNS side effects. These symptoms are uncommon and usually respond to a dose reduction. Rash, baldness, and hunger stimulation have all been reported on occasion. Sodium vaiproate has a number of impacts on hepatic function, including an increase in liver enzymes in plasma in up to 40% of patients, which frequently happens asymptomatically during the first few months of treatment.
Sodium vaiproate passes the placenta, and in humans, first-trimester valproate exposure has been linked to neural tube abnormalities including anencephaly and spina bifida in newborns. Pregnant women using Sodium Vaiproate should have their blood a-fetoprotein levels measured. Breast milk excretes sodium valproate. Breast-feeding by a mother taking Sodium Valproate, on the other hand, is unlikely to harm the kid.
Liver function should be checked before starting treatment and during the first six months, especially in individuals who are most at risk. Before beginning and before major surgery, there must be no unnecessary risk of bleeding. Renal impairment, pregnancy, breast-feeding, and systemic lupus erythematosus all require caution. Because sodium valproate is partly removed in the urine as a ketone metabolite, the urine ketone test may be misinterpreted. The abrupt cessation of therapy should be avoided. Sodium Valproate should not be taken during pregnancy or by women who are planning to have children.
Primary anti-epileptic drugs
Do not store at temperatures above 30°C. Keep out of the reach of youngsters and away from light.
Incepta Pharmaceuticals Ltd.
Disclaimer:The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website/ app.